This, together with the seemingly discrepant literature on Wnt-mediated effects on neuroblastoma cells, prompted us to identify bona fide Wnt target genes in neuroblastoma using RNA sequencing of SK-N-BE(2)-C cells treated with Wnt3a/Rspo2, and thereafter correlate the neuroblastoma Wnt signature with clinical parameters. This evidence concerns the gene RSPO2 and neuroblastoma.